These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15162151)

  • 1. A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.
    Liggins AP; Brown PJ; Asker K; Pulford K; Banham AH
    Br J Cancer; 2004 Jul; 91(1):141-9. PubMed ID: 15162151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
    Ait-Tahar K; Liggins AP; Collins GP; Campbell A; Barnardo M; Lawrie C; Moir D; Hatton C; Banham AH; Pulford K
    Br J Haematol; 2009 Aug; 146(4):396-407. PubMed ID: 19552722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.
    Liggins AP; Cooper CD; Lawrie CH; Brown PJ; Collins GP; Hatton CS; Pulford K; Banham AH
    Br J Haematol; 2007 Aug; 138(4):479-86. PubMed ID: 17608765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
    Ait-Tahar K; Liggins AP; Collins GP; Campbell A; Barnardo M; Cabes M; Lawrie CH; Moir D; Hatton C; Banham AH; Pulford K
    Haematologica; 2011 Jan; 96(1):78-86. PubMed ID: 20851862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
    Joseph-Pietras D; Gao Y; Zojer N; Ait-Tahar K; Banham AH; Pulford K; Rice J; Savelyeva N; Sahota SS
    Leukemia; 2010 Nov; 24(11):1951-9. PubMed ID: 20861911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics.
    Booman M; Douwes J; Glas AM; de Jong D; Schuuring E; Kluin PM
    J Pathol; 2006 Oct; 210(2):163-71. PubMed ID: 16823896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes.
    Watanuki-Miyauchi R; Kojima Y; Tsurumi H; Hara T; Goto N; Kasahara S; Saio M; Moriwaki H; Takami T
    Pathol Int; 2005 Jun; 55(6):324-30. PubMed ID: 15943789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum.
    Jäger D; Unkelbach M; Frei C; Bert F; Scanlan MJ; Jäger E; Old LJ; Chen YT; Knuth A
    Cancer Immun; 2002 Jun; 2():5. PubMed ID: 12747750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomic analysis of human sarcoma.
    Lee SY; Obata Y; Yoshida M; Stockert E; Williamson B; Jungbluth AA; Chen YT; Old LJ; Scanlan MJ
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2651-6. PubMed ID: 12601173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia.
    Guinn BA; Bland EA; Lodi U; Liggins AP; Tobal K; Petters S; Wells JW; Banham AH; Mufti GJ
    Biochem Biophys Res Commun; 2005 Oct; 335(4):1293-304. PubMed ID: 16112646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma.
    Uherova P; Ross CW; Schnitzer B; Singleton TP; Finn WG
    Am J Clin Pathol; 2001 Apr; 115(4):582-8. PubMed ID: 11293907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of a novel cancer/testis antigen gene CAGE.
    Cho B; Lim Y; Lee DY; Park SY; Lee H; Kim WH; Yang H; Bang YJ; Jeoung DI
    Biochem Biophys Res Commun; 2002 Apr; 292(3):715-26. PubMed ID: 11922625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serologic detection of diffuse large B-cell lymphoma-associated antigens.
    Liggins AP; Guinn BA; Hatton CS; Pulford K; Banham AH
    Int J Cancer; 2004 Jul; 110(4):563-9. PubMed ID: 15122589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2.
    Mainou-Fowler T; Overman LM; Dignum H; Wood K; Crosier S; Angus B; Proctor SJ; Anderson JJ
    Int J Oncol; 2008 Jan; 32(1):59-68. PubMed ID: 18097543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
    Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.
    Ono T; Kurashige T; Harada N; Noguchi Y; Saika T; Niikawa N; Aoe M; Nakamura S; Higashi T; Hiraki A; Wada H; Kumon H; Old LJ; Nakayama E
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3282-7. PubMed ID: 11248070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
    Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.